Potassium voltage-gated channel subfamily Q member 2 mRNA (KCNQ2 mRNA)

KCNQ2 mRNA encodes the Kv7.2 subunit of the voltage-gated potassium channel, which is essential for generating the M-current in the central nervous system. This current plays a critical role in stabilizing the resting membrane potential and controlling the frequency of neuronal firing. Mutations in the KCNQ2 gene lead to a spectrum of seizure disorders, ranging from self-limiting neonatal epilepsy to severe developmental and epileptic encephalopathy (DEE). While traditional pharmacology focuses on small-molecule openers of the KCNQ2 protein, modern genetic therapies target the KCNQ2 mRNA directly. These mRNA-targeted approaches, such as antisense oligonucleotides (ASOs), aim to either upregulate healthy protein production in cases of haploinsufficiency or silence toxic mutant alleles, offering a precision medicine approach to treating refractory pediatric epilepsies (UniProt: O43526; NIH: GeneReviews NBK1444).

Other names

Kv7.2 mRNAPotassium channel subunit alpha Kv7.2 mRNABFNC mRNAEBFN1 mRNAENB1 mRNAKCNA11 mRNA

Therapeutic strategies targeting KCNQ2 mRNA primarily involve antisense oligonucleotides (ASOs) designed to modulate gene expression. These can function by increasing the expression of the wild-type allele in haploinsufficiency cases (Targeted Augmentation of Nuclear Gene Output or TANGO technology) or by selectively degrading mRNA transcripts containing gain-of-function mutations to restore normal neuronal excitability (PubMed: 33164107, 35732151).